Ophthalmology Times

CONTINUE TO SITE

OR WAIT null SECS

Cataract Surgical Case Study Cataract Therapeutics Glaucoma Insights CME Activities Dry Eye Viewpoint Diabetic Eye Disease Viewpoints Cornea Updates Diabetic Eye Disease Podcast DME Therapy Dry Eye Concepts Dry Eye Flares Management of Dry Eye Viewpoints Ptosis WetAMD Viewpoints

Cataract Surgical Case Study Cataract Therapeutics Glaucoma Insights CME Activities Dry Eye Viewpoint Diabetic Eye Disease Viewpoints Cornea Updates Diabetic Eye Disease Podcast DME Therapy Dry Eye Concepts Dry Eye Flares Management of Dry Eye Viewpoints Ptosis WetAMD Viewpoints

View More Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

Cataract Clinical Diagnosis Cornea Glaucoma IOL OCT Ocular Allergy Ocular Surface Disease Pediatrics Refractive Retina Technology Therapeutic Cataract & Refractive Understanding Antibiotic Resistance

All News Blogs COVID-19

Expert Interviews

Medical World News

Expert Interviews Medical World News Podcasts Viewpoints Insights

Health Law & Policy

Personal Finance

Practice Management

Health Law & Policy Money Matters Personal Finance Practice Management

Conference Coverage

Conference Listing

Conference Coverage Conference Listing

Digital Edition

Europe Ophthalmology Times

Supplements and Featured Publications

Digital Edition Europe Ophthalmology Times Modern Retina Supplements and Featured Publications

Partners CME/CE Job Board Sponsored

Print Subscription

eNewsletter Print Subscription

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences and Ophthalmology Times. All rights reserved.

.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

Cataract Surgical Case Study
Cataract Therapeutics
Glaucoma Insights
CME Activities
Dry Eye Viewpoint
Diabetic Eye Disease Viewpoints
Cornea Updates
Diabetic Eye Disease Podcast
DME Therapy
Dry Eye Concepts
Dry Eye Flares
Management of Dry Eye Viewpoints
Ptosis
WetAMD Viewpoints

ClinicalSee All >

Cataract
Clinical Diagnosis
Cornea
Glaucoma
IOL
OCT
Ocular Allergy
Ocular Surface Disease
Pediatrics
Refractive
Retina
Technology
Therapeutic Cataract & Refractive
Understanding Antibiotic Resistance

Advertise
Contact Us
Editorial
Job Board
Terms and Conditions
Privacy
Do Not Sell My Personal Information

© 2021 MJH Life Sciences^™ and Ophthalmology Times. All rights reserved.

Once-daily timolol formulation OK'd

July 1, 2004

The FDA has approved a new drug application by ISTA Pharmaceuticals for the once-daily liquid formulation of timolol 0.5% as a therapy for glaucoma.

Related Content:

Advancement in TED treatment is a bright spot

Advancement in TED treatment is a bright spot

Comparable conscious sedation methods address individual patient needs

Comparable conscious sedation methods address individual patient needs

Investigators uncover health care disparities among US patients

Investigators uncover health care disparities among US patients